Zimmer Biomet Holdings Inc (NYSE:ZBH) announced a quarterly dividend on Thursday, June 14th, RTT News reports. Shareholders of record on Friday, June 29th will be given a dividend of 0.24 per share by the medical equipment provider on Tuesday, July 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Thursday, June 28th.
Zimmer Biomet has a payout ratio of 12.0% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Zimmer Biomet to earn $8.02 per share next year, which means the company should continue to be able to cover its $0.96 annual dividend with an expected future payout ratio of 12.0%.
ZBH stock opened at $111.76 on Friday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.69 and a quick ratio of 1.07. Zimmer Biomet has a 52-week low of $104.28 and a 52-week high of $133.49. The stock has a market cap of $22.67 billion, a price-to-earnings ratio of 13.92, a PEG ratio of 2.18 and a beta of 1.14.
Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, April 26th. The medical equipment provider reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.89 by $0.02. Zimmer Biomet had a net margin of 21.81% and a return on equity of 14.36%. The business had revenue of $2.02 billion during the quarter, compared to analysts’ expectations of $1.98 billion. During the same quarter last year, the company earned $2.13 earnings per share. The firm’s revenue was up 2.1% on a year-over-year basis. equities analysts anticipate that Zimmer Biomet will post 7.67 EPS for the current fiscal year.
In other Zimmer Biomet news, VP Tony W. Collins sold 1,330 shares of the firm’s stock in a transaction dated Monday, April 30th. The shares were sold at an average price of $116.73, for a total transaction of $155,250.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Katarzyna Mazur-Hofsaess sold 8,765 shares of the firm’s stock in a transaction dated Tuesday, May 22nd. The stock was sold at an average price of $113.61, for a total transaction of $995,791.65. Following the transaction, the insider now owns 25,447 shares of the company’s stock, valued at approximately $2,891,033.67. The disclosure for this sale can be found here. 0.71% of the stock is owned by company insiders.
ZBH has been the subject of several research reports. Evercore ISI initiated coverage on shares of Zimmer Biomet in a research note on Monday, April 2nd. They issued an “in-line” rating and a $115.00 target price for the company. Robert W. Baird cut shares of Zimmer Biomet from an “outperform” rating to a “neutral” rating in a research note on Friday, March 23rd. Morgan Stanley reduced their target price on shares of Zimmer Biomet from $150.00 to $148.00 and set an “overweight” rating for the company in a research note on Monday, February 26th. Citigroup reduced their target price on shares of Zimmer Biomet from $132.00 to $121.00 and set a “neutral” rating for the company in a research note on Tuesday, February 27th. Finally, Canaccord Genuity reiterated a “hold” rating and issued a $121.00 target price on shares of Zimmer Biomet in a research note on Thursday, April 12th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $137.71.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.